tigecycline / Generic mfg. - LARVOL DELTA

Characterization of tmexCD-toprJ-positive Klebsiella spp. from pediatric patients in a Chinese hospital. (PubMed, BMC Microbiol) - No abstract available

Journal • Pediatrics

Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an Elderly Patient with Advanced Lung Adenocarcinoma Treated with Osimertinib. (PubMed, Infect Drug Resist) - "We report a rare case of multidrug-resistant (MDR) Enterobacter cloacae pneumonia complicated by invasive pulmonary aspergillosis (IPA) in a 75-year-old male with lung adenocarcinoma who had been receiving osimertinib for 8 months. Prompt susceptibility-guided therapy with polymyxin B plus tigecycline (for MDR bacteria) and voriconazole (for aspergillosis) achieved complete resolution, highlighting the importance of rapid microbiological diagnosis and targeted antimicrobials in this vulnerable population."

Journal • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Antibiotic resistance patterns of Escherichia coli isolates in Passeriformes and non-Passeriformes: insights from migratory and resident avifauna. (PubMed, BMC Vet Res) - No abstract available

Journal

Genomic convergence of multidrug resistance, virulence-associated loci, and phage defense systems in Klebsiella pneumoniae from pharmaceutical wastewater in Bangladesh. (PubMed, Sci Rep) - "JU-BAEC-01 belongs to a phylogenetically distinct lineage, serotype O3b: KL150 with resistance to nearly all clinically relevant antibiotic classes except carbapenems and colistin, mediated by an extensive acquired resistome, including tmexCD3-toprJ3 (tigecycline), armA, aac(6')-Ib-cr, qnrB4, oqxAB, blaDHA-1, blaSHV-182, and blaTEM-1B, mostly carried on conjugative IncC, IncFIB, IncHI1B, and IncR plasmids. pneumoniae JU-BAEC-01 is a "perfect storm" pathogen that combines multi-drug resistance (MDR), hypervirulence, and a multilayered, highly developed defense against bacteriophages. Together, these findings highlight the environmental emergence of a genetically distinct, multidrug-resistant K. pneumoniae with substantial virulence potential and complex phage-host interaction capacity, underscoring the need for genomic surveillance of pharmaceutical wastewater systems."

Journal • Infectious Disease • Pneumonia

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials. (PubMed, Infection) - "Despite the growth of newer anti-MRSA agents, vancomycin remains clinically comparable for MRSA-confirmed SSTI, with apparent microbiological advantages of alternatives tempered by potential publication bias. Varying safety and pharmacological profiles of these agents emphasize the importance of individualized treatment selection."

Journal • Retrospective data • Hematological Disorders • Infectious Disease

Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? (PubMed, J Antimicrob Chemother) - "This study demonstrated the high in vitro efficacy of temocillin against 3GC-R Enterobacterales from BJIs, regardless of the underlying resistance mechanism. However, dosage adjustments based on the strain's MIC and the patient's renal function are crucial for optimal efficacy."

Journal • Infectious Disease

Distribution and antimicrobial resistance profiles of common blood culture isolates in a maternal and child health specialty hospital, Shenzhen (January 2021-October 2025), China. (PubMed, Front Microbiol) - "Among Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA) accounted for 22.2%, all susceptible to vancomycin, linezolid, and tigecycline. The high ESBL rate in Escherichia coli and the detection of a CRE isolate indicate emerging β-lactam resistance risks. Although MRSA was detected, complete susceptibility to glycopeptides was preserved, highlighting the importance of ongoing monitoring."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports. (PubMed, J Blood Med) - "Two allo-HSCT recipients whose febrile neutropenia persisted on empiric carbapenem were promptly escalated to imipenem/cilastatin/relebactam, alone or combined with aztreonam and tigecycline-before culture confirmation. Immediate empiric imipenem/cilastatin/relebactam for CRE-high-risk allo-HSCT recipients with febrile neutropenia rapidly controlled infections and permitted successful hematopoietic recovery. Prospective studies are warranted."

Journal • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Transplantation

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025). (PubMed, Microbiol Spectr) - "This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources...Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs50/90 were 1/4 and 0.5/1 mg/L, respectively...The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in Escherichia coli (ESCMID Global 2026) - No abstract available

Intraventricular tigecycline for post-neurosurgery ventriculitis due to XDR Acinetobacter baumannii (ESCMID Global 2026) - No abstract available

Surgery

Co-emergence of plasmid-borne tigecycline resistance genes tet(X4) and tmexCD1-toprJ1 in Raoultella ornithinolytica isolated from retail pork in Jiangsu province, China (ESCMID Global 2026) - No abstract available

Emergence of plasmid-mediated tigecycline, colistin and carbapenem resistance genes in E. coli isolated from minks in China (ESCMID Global 2026) - No abstract available

Standard- vs high-dose tigecycline in pneumonia due to carbapenem-resistant Acinetobacter baumannii: a propensity score-matched retrospective study (ESCMID Global 2026) - No abstract available

Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases

Colistin/sulbactam vs colistin/sulbactam plus high-dose tigecycline for the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia: a multi-centre randomised controlled trial (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pneumonia • Respiratory Diseases

Genomic decoding of tigecycline resistance and daptomycin non-susceptibility in Enterococcus faecium (ESCMID Global 2026) - No abstract available

In vivo evolution of tigecycline resistance in carbapenem-resistant Acinetobacter baumannii during tigecycline treatment (ESCMID Global 2026) - No abstract available

Preclinical

A multi-centre cohort study of tigecycline effectiveness and safety in patients with carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii co-infection (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pneumonia

Comparative effectiveness of polymyxin B combined with sulbactam vs polymyxin B combined with tigecycline in treatment of carbapenem-resistant Acinetobacter baumannii pneumonia: a retrospective observational study (ESCMID Global 2026) - No abstract available

HEOR • Observational data • Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases

Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in Escherichia coli (ESCMID Global 2026) - No abstract available

Tigecycline-selected tyrosine kinase mutation in Klebsiella pneumoniae triggers metabolic rewiring and increased phage susceptibility without affecting virulence (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia

Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in China: A Nationwide Multicenter Study. (PubMed, Int J Antimicrob Agents) - "CZA-resistant CRKP in China are uncommon but widely distributed, driven mainly by epidemic ST11-KL64/KL47 lineages with extensive multidrug resistance and no convergence with classical hypervirulence. In the small subset of KPC-2-only isolates, resistance correlated with increased blaKPC-2 expression/copy number and efflux involvement, with frequent co-occurrence of porin structural variants."

Clinical • Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Prevalence of Inducible Clindamycin Resistance Staphylococcus aureus Associated with Wound Infection in Central Nepal. (PubMed, J Nepal Health Res Counc) - "A high rate of inducible clindamycin resistance among MRSA was observed. To identify the status of antibiotic resistance among S. aureus, further genomic-based studies are required."

Journal • Infectious Disease

Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations. (PubMed, J Antimicrob Chemother) - "These findings enhance our understanding of the diversity of tmexCD-toprJ-carrying plasmids. The convergence of tmexCD-toprJ with carbapenemase and polymyxin resistance genes in clinically prevalent plasmids underscores an urgent need for enhanced surveillance targeting complete genetic environments."

Journal • Infectious Disease • Pneumonia

FORMaT-EVOLVE: Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: The University of Queensland

New P2 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases